We’re excited to share that two of our scientific studies, each exploring different aspects of our non-opioid implantable anesthetics for postoperative pain relief in spine surgery, were published ahead of print:

In Regional Anesthesia & Pain Medicine, first-in-human safety results demonstrated a 13x systemic safety margin with no serious adverse events linked to our implantable anesthetics.¹

In the preceding paper in the International Journal of Pharmaceutics, our preclinical sheep study showed sustained high local concentrations of bupivacaine at the surgical site, while systemic levels remained several orders of magnitute lower, supporting a strong and favorable risk-benefit profile.²

Together, these studies highlight our commitment to evidence-based innovation, developing solutions that are not only novel, but also grounded in rigorous science and designed to meet real clinical needs.

1. Jonkman H, van Tol FR, Bruins S, Steverink JG, Benneker LM, Geuze R, de Baat P, Rovers M, Oosterman BJ, Verlaan JJ. Novel implantable anesthetic for spine fixation surgery: phase Ib safety results of a sustained-release formulation of bupivacaine. Reg Anesth Pain Med. 2025 May 20:rapm-2025-106551. doi: 10.1136/rapm-2025-106551. Epub ahead of print. PMID: 40393774.
2. Steverink JG, van Tol FR, Bruins S, Amponsah KB, Marvela J, Smorenburg AJ, Jonkman HR, Oosterman BJ, van Dijk MR, Malda J, Piluso S, Verlaan JJ. Testing a new sustained-release local anesthetic formulation specifically designed for spine surgery in a sheep model. Int J Pharm. 2025 May 17:125731. doi: 10.1016/j.ijpharm.2025.125731. Epub ahead of print. PMID: 40389071.